Alembic Pharmaceuticals Ltd today announced that it has received final approval from the US Food & Drug Administration for its Abbreviated New Drug Application Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg.
Alembic Pharmaceuticals Ltd has received final approval from the US Food & Drug Administration for its Abbreviated New Drug Application Fluorouracil Injection USP, 2.5 g/50 mL (50 mg/mL) Pharmacy Bulk Vial.
Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug Administration for its Abbreviated New Drug Application Docetaxel Injection.
The Board of Directors of Alembic Pharmaceuticals Limited, at its meeting held today have approved the financial results of the company for the period ended December 31, 2022 - Q3FY23 and 9MFY23.
Alembic Pharmaceuticals Ltd today announced that it has received tentative approval from the US Food & Drug Administration for its Abbreviated New Drug Application, Acalabrutinib Capsules, 100 mg.